1. Home
  2. AMZE vs COCP Comparison

AMZE vs COCP Comparison

Compare AMZE & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amaze Holdings Inc.

AMZE

Amaze Holdings Inc.

HOLD

Current Price

$0.38

Market Cap

14.3M

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$1.04

Market Cap

15.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMZE
COCP
Founded
2019
2006
Country
United States
United States
Employees
4
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3M
15.3M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
AMZE
COCP
Price
$0.38
$1.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$6.00
AVG Volume (30 Days)
1.4M
56.2K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
8.02
EPS
N/A
N/A
Revenue
N/A
$12,712,091.00
Revenue This Year
$6,741.66
N/A
Revenue Next Year
$100.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.86
52 Week High
$11.76
$2.19

Technical Indicators

Market Signals
Indicator
AMZE
COCP
Relative Strength Index (RSI) 47.35 55.36
Support Level $0.34 $1.01
Resistance Level $0.42 $1.10
Average True Range (ATR) 0.05 0.07
MACD -0.00 0.01
Stochastic Oscillator 61.93 89.54

Price Performance

Historical Comparison
AMZE
COCP

About AMZE Amaze Holdings Inc.

Amaze Holdings Inc is a software company dedicated to empowering creators by providing comprehensive software solutions and services that facilitate e-commerce, social commerce, integrated commerce selling experiences, and the distribution of a premium wine brand. The group offers an end-to-end, creator-powered commerce platform offering tools for seamless product creation, modern e-commerce solutions, and scalable managed services.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Share on Social Networks: